Manfred Wirth1, Axel Heidenreich2, Jürgen E Gschwend3, Thierry Gil4, Stefan Zastrow5, Michael Laniado5, Joachim Gerloff6, Michael Zühlsdorf6, Giacomo Mordenti6, Wolfgang Uhl6, Heinrich Lannert6. 1. Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany. Electronic address: Manfred.Wirth@uniklinikum-dresden.de. 2. Department of Urology, RWTH Aachen University, Aachen, Germany. 3. Department of Urology, Technical University of Munich Klinikum Rechts der Isar, Munich, Germany. 4. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 5. Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany. 6. Merck KGaA, Darmstadt, Germany.
Abstract
BACKGROUND: EMD 525797 (DI17E6) is a deimmunized, humanized monoclonal immunoglobulin G2 antibody against the αv subunit of human integrins. Blocking αv integrins may be an effective strategy for inhibiting prostate cancer (PCa) metastasis. OBJECTIVE: Evaluate EMD 525797 safety/tolerability and pharmacokinetics (PK) in castration-resistant PCa patients. Secondary objectives included antitumor activity assessments. DESIGN, SETTING, AND PARTICIPANTS: A phase 1 open-label study in 26 patients (four European centers). Eligible patients (≥ 18 yr) had histologically proven PCa with bone metastases after prior chemotherapy and evidence of progressive disease (PD) based on prostate-specific antigen (PSA) values. INTERVENTION: Patients received three intravenous EMD 525797 infusions (250, 500, 1000, or 1500 mg every 2 wk). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Treatment-emergent adverse events (TEAEs) and dose-limiting toxicities (DLTs) were assessed. PK parameters were calculated according to noncompartmental standard methods. Antitumor activity measures were response after 6 wk, changes in PSA levels, and pain interference total score. Descriptive statistics were used. RESULTS AND LIMITATIONS: Patients were treated for a mean of 16.8 ± 16.7 wk. No DLTs were reported in any of the cohorts. All patients experienced TEAEs, which were considered drug-related in 11 patients. Four deaths occurred during the trial and were considered not related to EMD 525797. EMD 525797 showed dose-dependent, nonlinear PK. Eighteen of 26 patients did not show PD for ≥ 18 wk. Two patients (500-mg cohort), treated for 42.4 and 76.3 wk, had clinically significant PSA reductions and pain relief, including one patient with confirmed partial response. This trial was not specifically designed to assess clinical activity, and further investigations are needed in randomized controlled trials. CONCLUSIONS: No DLTs were reported in any of the evaluated cohorts. There was evidence of clinical activity. For the currently ongoing phase 2 trial, EMD 525797 doses of 750 and 1500 mg every 3 wk were chosen. TRIAL REGISTRATION: NCT00958477 (EMR 62242-002).
BACKGROUND: EMD 525797 (DI17E6) is a deimmunized, humanized monoclonal immunoglobulin G2 antibody against the αv subunit of human integrins. Blocking αv integrins may be an effective strategy for inhibiting prostate cancer (PCa) metastasis. OBJECTIVE: Evaluate EMD 525797 safety/tolerability and pharmacokinetics (PK) in castration-resistant PCa patients. Secondary objectives included antitumor activity assessments. DESIGN, SETTING, AND PARTICIPANTS: A phase 1 open-label study in 26 patients (four European centers). Eligible patients (≥ 18 yr) had histologically proven PCa with bone metastases after prior chemotherapy and evidence of progressive disease (PD) based on prostate-specific antigen (PSA) values. INTERVENTION: Patients received three intravenous EMD 525797 infusions (250, 500, 1000, or 1500 mg every 2 wk). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Treatment-emergent adverse events (TEAEs) and dose-limiting toxicities (DLTs) were assessed. PK parameters were calculated according to noncompartmental standard methods. Antitumor activity measures were response after 6 wk, changes in PSA levels, and pain interference total score. Descriptive statistics were used. RESULTS AND LIMITATIONS: Patients were treated for a mean of 16.8 ± 16.7 wk. No DLTs were reported in any of the cohorts. All patients experienced TEAEs, which were considered drug-related in 11 patients. Four deaths occurred during the trial and were considered not related to EMD 525797. EMD 525797 showed dose-dependent, nonlinear PK. Eighteen of 26 patients did not show PD for ≥ 18 wk. Two patients (500-mg cohort), treated for 42.4 and 76.3 wk, had clinically significant PSA reductions and pain relief, including one patient with confirmed partial response. This trial was not specifically designed to assess clinical activity, and further investigations are needed in randomized controlled trials. CONCLUSIONS: No DLTs were reported in any of the evaluated cohorts. There was evidence of clinical activity. For the currently ongoing phase 2 trial, EMD 525797 doses of 750 and 1500 mg every 3 wk were chosen. TRIAL REGISTRATION: NCT00958477 (EMR 62242-002).
Authors: Huimin Lu; Nicholas Bowler; Larry A Harshyne; D Craig Hooper; Shiv Ram Krishn; Senem Kurtoglu; Carmine Fedele; Qin Liu; Hsin-Yao Tang; Andrew V Kossenkov; William K Kelly; Kerith Wang; Rhonda B Kean; Paul H Weinreb; Lei Yu; Anindita Dutta; Paolo Fortina; Adam Ertel; Maria Stanczak; Flemming Forsberg; Dmitry I Gabrilovich; David W Speicher; Dario C Altieri; Lucia R Languino Journal: Matrix Biol Date: 2018-03-09 Impact factor: 11.583
Authors: B Milojkovic Kerklaan; S Slater; M Flynn; A Greystoke; P O Witteveen; M Megui-Roelvink; F de Vos; E Dean; L Reyderman; L Ottesen; M Ranson; M P J Lolkema; R Plummer; R Kristeleit; T R J Evans; J H M Schellens Journal: Invest New Drugs Date: 2016-04-02 Impact factor: 3.850
Authors: Yu-Chen Lee; Song-Chang Lin; Guoyu Yu; Chien-Jui Cheng; Bin Liu; Hsuan-Chen Liu; David H Hawke; Nila U Parikh; Andreas Varkaris; Paul Corn; Christopher Logothetis; Robert L Satcher; Li-Yuan Yu-Lee; Gary E Gallick; Sue-Hwa Lin Journal: Cancer Res Date: 2015-11-03 Impact factor: 12.701
Authors: Mark Sutherland; Andrew Gordon; Steven D Shnyder; Laurence H Patterson; Helen M Sheldrake Journal: Cancers (Basel) Date: 2012-10-26 Impact factor: 6.639
Authors: Wolfgang Uhl; Michael Zühlsdorf; Thomas Koernicke; Ulf Forssmann; Andreas Kovar Journal: Invest New Drugs Date: 2013-11-19 Impact factor: 3.850